The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.
 
Andrew Lachlan Schmidt
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Chris Labaki
No Relationships to Disclose
 
Babar Bashir
Research Funding - Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Ikena Oncology (Inst); Syros Pharmaceuticals (Inst)
 
Jessica M. Clement
Employment - eviCore healthcare (I)
Consulting or Advisory Role - Anthem
Travel, Accommodations, Expenses - Anthem
 
Natasha Catherine Edwin
No Relationships to Disclose
 
Daniel Blake Flora
Other Relationship - Bexion
 
Jennifer Girard
No Relationships to Disclose
 
Shuchi Gulati
Consulting or Advisory Role - Puma Biotechnology
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Conquer Cancer Foundation
 
Clara Hwang
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - Genzyme
Research Funding - AstraZeneca (Inst); Bausch Health (Inst); Bayer (Inst); Genentech (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Chinmay Jani
No Relationships to Disclose
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Ruben A. Mesa
Honoraria - Abbvie; AOP Orphan Pharmaceuticals; BMS; Geron; Novartis; shire; Sierra Oncology
Consulting or Advisory Role - Baxalta; Galena Biopharma; Incyte; Novartis
Research Funding - Abbvie (Inst); Celgene (Inst); CTI (Inst); Genentech (Inst); Gilead Sciences (Inst); Imago Pharma (Inst); Incyte (Inst); NS Pharma (Inst); Pfizer (Inst); Pharmaessentia (Inst); Promedior (Inst)
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Incyte; Novartis; Pharmaessentia
 
Gil Redelman-Sidi
No Relationships to Disclose
 
Sanjay Mishra
No Relationships to Disclose
 
Jeremy Lyle Warner
Stock and Other Ownership Interests - HemOnc.org
Consulting or Advisory Role - IBM; Westat
Travel, Accommodations, Expenses - IBM
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; IQvia; Janssen Oncology; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel